Sanofi has made its single largest investment in China to date by pouring roughly €1 billion ($1.05 billion) into a new ...

Former FDA commissioner Scott Gottlieb came out against president-elect Trump’s choice of Robert F. Kennedy Jr. to lead the ...

Johnson & Johnson has filed for two new pediatric indications as it looks to position its blockbuster immunotherapy Tremfya ...

Biocon Biologics scored an FDA approval for its Stelara biosimilar, marketed as Yesintek, the company announced Monday.

Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...

Novocure announced Monday morning that its electrical field wearable device combined with chemotherapy passed a late-stage ...

Agenus Bio is launching a CDMO arm using facilities in Berkeley and Emeryville, CA, while cutting spending to $100M by 2025.

Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...

Merus reported updated Phase 2 trial results for petosemtamab in head and neck cancer, showing 40.4% overall response rate ...

Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...